Infinity Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Seth Tasker

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.4yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Seth Tasker rispetto agli utili di Infinity Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	-US$41m
Mar 31 2023	n/a	n/a	-US$43m
Dec 31 2022	n/a	n/a	-US$44m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	n/a	n/a	-US$45m
Sep 30 2021	n/a	n/a	-US$44m
Jun 30 2021	n/a	n/a	-US$43m
Mar 31 2021	n/a	n/a	-US$41m
Dec 31 2020	US$1m	US$386k	-US$40m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$43m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$653k	US$368k	-US$47m
Sep 30 2019	n/a	n/a	-US$44m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	n/a	n/a	-US$11m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$41m
Dec 31 2017	US$1m	US$320k	-US$42m
Sep 30 2017	n/a	n/a	-US$57m
Jun 30 2017	n/a	n/a	-US$70m
Mar 31 2017	n/a	n/a	US$88k
Dec 31 2016	US$404k	US$266k	-US$30m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Seth sia ragionevole rispetto ad aziende di dimensioni simili nel mercato German.

Compensazione vs guadagni: La retribuzione di Seth è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Seth Tasker (44 yo)

7.4yrs

Mandato

US$1,435,444

Compensazione

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anthony Evnin	Independent Director	17.3yrs	US$93.08k	0.24% € 608.3
Norman Selby	Lead Independent Director	11.8yrs	US$125.82k	0.017% € 42.4
David Beier	Independent Director	5.7yrs	US$85.58k	0.0097% € 24.8
Roy Steven Herbst	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
David Munn	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
F. Hodi	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Richard B. Gaynor	Independent Director	3.8yrs	US$83.08k	0% € 0
Dmitry Gabrilovich	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Jeffery Kutok	Chairman of Scientific Advisory Board	3.8yrs	US$759.67k	Nessun dato
Samuel Agresta	Chair of Clinical Advisory Board	no data	US$73.08k	0.012% € 29.9
Toni Choueiri	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Michael Postow	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato

5.8yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di I3F sono considerati esperti (durata media dell'incarico 5.8 anni).

Infinity Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.50 loss per share (vs US$0.53 loss in FY 2021)

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2021)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021)

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 1Q 2021)

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings released: US$0.53 loss per share (vs US$0.68 loss in FY 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: €4.00

New 90-day high: €2.00

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

New 90-day high: €1.95

New 90-day high: €1.45

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - €1.03